Udvalget for Humanmedicinske Lægemidler (CHMP) fandt, at de gavnlige virkninger af Ceprotin er større end risiciene for patienter med medfødt svær protein C- mangel.
The Committee for Medicinal products for Human Use (CHMP) decided that CEPROTIN’ s benefits are greater than its risks for patients with severe congenital protein C deficiency.